172 related articles for article (PubMed ID: 38226018)
1. Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets.
Wang J; Zhao Y; Liao P; Huang S; Huang Y; Chen S; Li Y; Zhong L
Blood Sci; 2024 Jan; 6(1):e00181. PubMed ID: 38226018
[TBL] [Abstract][Full Text] [Related]
2. Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.
Huang S; Zhao Y; Liao P; Wang J; Li Z; Tan J; Zha X; Chen S; Li Y; Zhong L
Front Oncol; 2022; 12():1014904. PubMed ID: 36439426
[TBL] [Abstract][Full Text] [Related]
3. Increased exhausted CD8
Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
[TBL] [Abstract][Full Text] [Related]
4. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
[No Abstract] [Full Text] [Related]
5. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
7. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
8. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
9. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.
Tan J; Yu Z; Huang J; Chen Y; Huang S; Yao D; Xu L; Lu Y; Chen S; Li Y
Biomark Res; 2020; 8():6. PubMed ID: 32082573
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer.
Zou W; Huang R; Li P; Liu X; Huang Q; Yue J; Liu C
J Infect Public Health; 2023 Apr; 16(4):542-550. PubMed ID: 36801634
[TBL] [Abstract][Full Text] [Related]
11. Increased TOX expression associates with exhausted T cells in patients with multiple myeloma.
Zhao Y; Liao P; Huang S; Deng T; Tan J; Huang Y; Zhan H; Li Y; Chen S; Zhong L
Exp Hematol Oncol; 2022 Mar; 11(1):12. PubMed ID: 35246241
[TBL] [Abstract][Full Text] [Related]
12. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and TIGIT Are Highly Co-Expressed on CD8
Xu L; Liu L; Yao D; Zeng X; Zhang Y; Lai J; Zhong J; Zha X; Zheng R; Lu Y; Li M; Jin Z; Hebbar Subramanyam S; Chen S; Huang X; Li Y
Front Oncol; 2021; 11():686156. PubMed ID: 34490086
[TBL] [Abstract][Full Text] [Related]
14. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
[TBL] [Abstract][Full Text] [Related]
15. Increased TIGIT
Luo Q; Fu P; Guo Y; Fu B; Guo Y; Huang Q; Huang Z; Li J
Exp Ther Med; 2022 Oct; 24(4):642. PubMed ID: 36160887
[TBL] [Abstract][Full Text] [Related]
16. Expression of the immune checkpoint receptor TIGIT in seminoma.
Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
[TBL] [Abstract][Full Text] [Related]
17. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
[TBL] [Abstract][Full Text] [Related]
18. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
[TBL] [Abstract][Full Text] [Related]
19. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
20. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
